Andrew D. Luber, Pharm.D.
President & Chief Executive Officer
Dr. Andrew D. Luber serves as President and Chief Executive Officer for Virion Therapeutics, LLC. He is one of the founders of Virion Therapeutics, LLC and has been successfully providing corporate leadership and oversight to the company since its inception in 2018. He is a clinical pharmacist with over 25 years of leadership experience in drug development and clinical research. His most recent experience was as Vice President, Clinical Pharmacology for Moerae Matrix, Inc., helping advance a novel anti-fibrotic and anti-inflammatory peptide into human clinical trials. Dr. Luber was a clinical investigator in more than forty clinical trials as Executive Director of Research for Pacific Oaks Medical Group and Tower ID Research in Los Angeles, CA., including four Phase 1a/b studies.
Dr. Luber has authored numerous textbook chapters and articles in peer-reviewed journals and online resources in human immunodeficiency virus (HIV) pharmacology and pharmacokinetics. He authored the American Academy of HIV Medicine’s Self-Directed Study Guide’s Pharmacology and Pharmacokinetic sections. In addition, he was a core faculty member in the development of The Viral Hepatitis Mid-Level Provider Certification Program for the American Association for Study of Liver Diseases. Dr. Luber has worked with many different pharmaceutical and biotechnology companies as a clinical study investigator, speakers’ bureau presenter, steering committee, and advisory board member and served as a clinical consultant to large and early-stage pharmaceutical companies. Dr. Luber received his B.S. Pharm. and Pharm.D. from Temple University School of Pharmacy, Philadelphia, PA. He completed his residency in pharmacy practice and infectious diseases and his research fellowship in infectious diseases pharmacotherapy at the University of California, San Francisco, School of Pharmacy.